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Abstract Previous studies of pancreatic ductal adenocar-
cinoma (PDAC) have demonstrated that the addition of
tumor grade to the 7th American Joint Committee on
Cancer (AJCC) staging can provide improved prognosti-
cation and that the recently proposed 8th edition AJCC
staging exhibited superior reproducibility to the 7th edition
in resectable PDAC. Thus, we aimed to combine tumor
grade and 8th AJCC stage to develop a refined staging
scheme for resectable PDAC. We analyzed 7719 patients
with resectable PDAC from the 2004–2012 Surveillance,
Epidemiology, and End Results database. We performed
recursive partitioning analysis (RPA) to objectively incor-
porate tumor grade with 8th AJCC stage into a novel
staging system. The performance of the proposed RPA
staging was assessed against the 8th AJCC staging in terms
of discriminatory ability and prognostic homogeneity. For
each 8th AJCC stage, survival was significantly worse for
high-grade versus low-grade tumors. RPA divided
resectable PDAC into five stages: RPA-IA (low-grade
T1N0), RPA-IB (high-grade T1N0 or low-grade T2N0),
RPA-IIA (high-grade T2N0 or low-grade T3N0/T1–
T3N1), RPA-IIB (high-grade T3N0/T1–T3N1 or low-grade
T1–T3N2), and RPA-III (high-grade T1–T3N2; median
survival: 42, 26, 19, 15, and 12 months, respectively;
P\ 0.001). The RPA staging outperformed the 8th AJCC
classifications in terms of discrimination (concordance
index, 0.585 versus 0.565; P\ 0.001) and prognostic
homogeneity. Tumor grade can provide additional prog-
nostic information to the 8th AJCC staging. The proposed
RPA staging is a superior risk-stratified tool to the 8th
AJCC staging and is not substantially more complex.
Keywords Pancreatic ductal adenocarcinoma  American
Joint Committee on Cancer staging  Recursive partitioning
analysis  Surveillance, Epidemiology, and End Results 
Extrapancreatic extension
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the most
common malignancy in the pancreas and the seventh
leading cause of cancer-related death worldwide [1].
Radical resection offers the only chance for cure, but
patients with resectable PDAC have high incidence of
postsurgical recurrence and dismal prognosis [2].
Conventionally, the outcomes of resectable PDAC are
predicted based on the American Joint Committee on
Cancer (AJCC) TNM classification, which involves the
tumor invasion depth and lymph node status [3]. However,
these clinicopathological factors cannot present a complete
prognostic picture, and survival within a particular stage is
highly variable [4].
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Several previous studies have demonstrated the prog-
nostic value of tumor grade in patients with PDAC [4–8].
Additionally, Wasif et al. [7] combined tumor grade and
the 7th AJCC stage into a new staging scheme which
exhibited superior survival discrimination to the 7th AJCC
staging scheme. However, this new staging was based on
arbitrarily advancing patients in the presence of high tumor
grade to the next higher stage level, which is method-
ologically not sound [9]. Moreover, several studies have
questioned the clinical relevance and reproducibility of the
7th AJCC T and N classification for patients with PDAC
[10].
In the recently proposed 8th AJCC staging scheme [9],
tumor size was the only accounted factor to determine the
T classification for resectable PDAC (T1, T2, and T3:
B2 cm, [2 cm and B4 cm, and [4 cm, respectively)
regardless of the involvement of peripancreatic soft tissue,
whereas node-positive disease was further classified into
N1 (1–3 positive nodes) and N2 stage (C4 positive nodes).
In a recent multi-institutional study of patients with
resectable PDAC, although the reproducibility of the 8th
edition T classification was superior to the 7th edition, the
predictive accuracy of the 7th and 8th AJCC staging
schemes was comparable, suggesting a room for
improvement of the 8th staging [9].
In the present study, we developed a refined staging
scheme for resectable PDAC by using the recursive parti-
tioning analysis (RPA) which can achieve the optimized
combination of tumor grade and 8th AJCC stage. The aim
of this study is to improve the prognostic performance of
the 8th AJCC staging without increasing complexity.
Patients and methods
Study cohort
The National Cancer Institute’s Surveillance, Epidemiol-
ogy, and End Results (SEER) program collects cancer
incidence, treatment, and survival data from 18 population-
based cancer registries covering approximately 28 % of the
US population. Using the SEER database (18 registries),
we identified 17,379 patients with PDAC (ICD-O-3 codes:
8140, 8150, 8210, 8211, 8251, 8260, 8261, 8263, 8480,
8481, 8490, 8500, and 8503) from January 2004 to
December 2012. Patients with a history of prior malig-
nancy, carcinoma in situ, locally unresectable tumor (T4
classification of the 6th edition AJCC scheme, which is
identical with the 7th edition), distant metastasis, and
missing information regarding tumor grade, tumor size, 6th
AJCC M classification, and number of positive lymph
nodes were excluded. The final study cohort consisted of
7719 patients.
Examined covariates included race, age, gender, and
marital status, year of diagnosis, SEER region, tumor
grade, tumor location, tumor size, positive node count, and
examined node count. All patients were restaged by the 8th
AJCC staging scheme. Tumor grades 1 and 2 were defined
as a ‘‘low-grade’’ group and tumor grades 3 and 4 as a
‘‘high-grade’’ group.
Statistical analysis
Overall survival (OS) was the primary outcome of interest.
Multivariate Cox regression was used to examine the
association between tumor grade and hazard ratio (HR) for
death after adjusted for other clinicopathologic factors. The
Kaplan–Meier method and log-rank tests were used to
compare OS between patients with low-grade and high-
grade tumors within each 8th AJCC stage.
To develop a refined staging system which incorporated
tumor grade together with 8th AJCC stage, recursive par-
titioning analysis (RPA) [11, 12] was performed to derive
new RPA stages by objectively regrouping the following
ten patient subgroups: low- and high-grade 8th IA (T1N0),
low- and high-grade 8th IB (T2N0), low- and high-grade
8th IIA (T3N0), low- and high-grade 8th IIB (T1–T3N1),
and low- and high-grade 8th III (T1–T3N2). The RPA
algorithm is based on the optimized binary partition of
these subgroups which results in new subgroups with rel-
atively homogeneous survival performance [11, 12]. Mul-
tivariate Cox regression was used to examine the
association between the RPA stage and hazard ratio (HR)
for death after adjustment for clinicopathologic factors.
Internal validation of the RPA staging scheme was per-
formed by using bootstrap with 1000 resamples, which
quantified model overfit.
The prognostic performance of the RPA staging
scheme was assessed against the 8th AJCC staging
scheme in terms of discrimination and prognostic homo-
geneity. The discriminatory capacity of the staging
schemes was quantified using the concordance index (C-
index) [13]. The value of the C-index ranges from 0.5 to
1.0, with 0.5 indicating a random chance and 1.0 indicating
a perfect ability to correctly discriminate the outcome with
the staging system; that is, the larger C-index, the superior
discriminatory capacity. Additionally, we evaluated the
prognostic homogeneity of the RPA staging scheme against
the 8th AJCC staging scheme: Within each RPA stage, OS
by 8th AJCC stages was compared using the Kaplan–Meier
method with log-rank tests.
Statistical significance was set as P\ 0.05 in a two-
tailed test. The statistical analyses were performed using
SAS v. 9.3 (SAS Institute, Cary, NC, USA), IBM SPSS
Statistics for Windows v.19.0 (IBM Corp., Armonk, NY,
USA), and R v. 3.3.1 (http://www.r-project.org).
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Results
Table 1 summarizes the patient characteristics of the study
cohort (7719 cases). The majority of the patients were
classified as 8th AJCC T2 disease (59.2 %) and node-
positive disease (65.7 %). The median numbers of positive
and examined node counts were 1 (interquartile range
[IQR] 0–3) and 13 (IQR 8–20), respectively. The median
survival for patients in the study cohort was 18 months.
After adjusted for race, year of diagnosis, age, sex,
marital status, SEER region, tumor site, 8th T and N
classification, and examined node count, high tumor grade
was significantly associated with increased risk of death
(HR 1.37; 95 % CI 1.29–1.44; P\ 0.001). For each 8th
AJCC stage, survival was significantly worse with high-
grade versus low-grade disease (P\ 0.01, P\ 0.001,
P = 0.04, P\ 0.001, and P\ 0.001 in 8th stage IA, IB,
IIA, IIB, and III, respectively; Fig. 1a–e). Of note, patients
with 8th stage IA disease (median survival: 36 months)
were further stratified into subgroups with remarkably
different OS, and an almost 20-month difference of median
survival was identified between patients with low-grade
tumor and those with high-grade tumor (42 vs. 23 months,
P\ 0.01; Fig. 1a).
The RPA algorithm classified patients with
resectable PDAC into the following five stage groups
(Fig. 2): RPA-IA (low-grade T1N0), RPA-IB (high-grade
T1N0 or low-grade T2N0), RPA-IIA (high-grade T2N0,
low-grade T3N0, or low-grade T1–T3N1), RPA-IIB (high-
grade T3N0, high-grade T1–T3N1, or low-grade T1–
T3N2), and RPA-III (high-grade T1–T3N2). The RPA-IA,
RPA-IB, RPA-IIA, RPA-IIB, and RPA-III stage groups
included 477 (6.2 %), 1176 (15.2 %), 2834 (36.7 %), 2492
(32.3 %), and 740 (9.6 %) patients, respectively. The cor-
responding median survival was 42, 26, 19, 15, and
12 months, respectively (P\ 0.001; Fig. 3). After adjust-
ment for race, year of diagnosis, age, sex, marital status,
SEER region, tumor site, tumor grade, and examined node
count, we confirmed that a higher RPA stage was associ-
ated with an increased risk of death (RPA-IB vs. RPA-IA:
HR, 1.49; RPA-IIA vs. RPA-IA: HR, 2.15; RPA-IIB vs.
RPA-IA: HR 2.86; RPA-III vs. RPA-IA: HR, 3.96;
P\ 0.001 for all).
The RPA staging achieved a C-index of 0.585 (95 % CI
0.576–0.594), which was superior to the 8th AJCC staging
scheme (C-index, 0.565; 95 % CI 0.556–0.573;
P\ 0.001). The bootstrap-corrected C-index for the RPA
staging maintained to be 0.585, indicating minimal evi-
dence of model overfit.
As shown in Table 2 and Fig. 4a–c, the RPA staging
exhibited excellent prognostic homogeneity when assessed
against the 8th AJCC staging; that is, for patients within
each RPA stage, survival was homogeneous when stratified
by 8th AJCC stages. Of note, patients with high-grade
T1N0 and low-grade T2N0 tumors, who were classified
into 8th stage IA and IB, respectively (median survival, 36
and 24 months, respectively), actually have similar sur-
vival (median survival, 23 and 26 months, respectively;
P = 0.92) and were both classified into RPA-IB (Fig. 4a).
Table 1 Clinicopathologic characteristics of the study cohort of
patients with resectable PDAC (N = 7791)
Variable Median (IQR)/N (%)
Age, years 66 (58, 74)
Race
White 6332 (82.0 %)
Black 806 (10.4 %)
Other 581 (7.6 %)
Sex
Male 3906 (50.6 %)
Female 3813 (49.4 %)
Marital status
Married 4803 (62.2 %)
Unmarried 203 (2.6 %)
Unknown 2713 (35.1 %)
Year of diagnosis
2004-2006 2177 (28.2 %)
2007-2009 2678 (34.7 %)
2010-2012 2864 (37.1 %)
SEER region
Midwest 1199 (15.5 %)
Northeast 1454 (18.8 %)
South 1382 (17.9 %)
West 3684 (47.7 %)
Tumor site
Head 5993 (77.6 %)
Body 440 (5.7 %)
Tail 602 (7.8 %)




Tumor size 31 (25, 40)
B2 cm (8th T1) 1333 (17.3 %)
[2 cm and B4 cm (8th T2) 4569 (59.2 %)
[4 cm (8th T3) 1817 (23.5 %)
Positive node count 1 (0, 3)
0 (8th N0) 2650 (34.3 %)
1–3 (8th N1) 2571 (33.3 %)
C4 (8th N2) 2498 (32.4 %)
Examined node count 13 (8, 20)
PDAC pancreatic ductal adenocarcinoma, IQR interquartile range,
SEER surveillance, epidemiology, and end results
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Fig. 1 Overall survival for the study cohort of 7719 patients with
resectable pancreatic ductal adenocarcinoma. Overall survival of
patients with 8th AJCC a IA, b IB, c IIA, d IIB, and e III disease
when stratified by tumor grade. Significant prognostic heterogeneity
was identified in all 8th AJCC stages
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In contrast, for patients within each 8th AJCC stage, the
RPA staging can further stratify the patients into subgroups
with remarkably different OS (P\ 0.01, P\ 0.001,
P = 0.04, P\ 0.001, and P\ 0.001 in 8th stage IA, IB,
IIA, IIB, and III, respectively; Table 2).
Discussion
Grade is a measure of the degree of tumor differentiation.
For PDAC, histologic grade is based on the extent of
glandular differentiation. Several previous studies have
detected the association between high tumor grade and
adverse prognosis in patients with resected PDAC [4–8]. In
this study of patients with resectable PDAC from the SEER
database, we demonstrated significant prognostic hetero-
geneity within each 8th AJCC stage stratified by tumor
grade, which verifies the prognostic value of tumor grade
and suggests a room for improvement in the 8th AJCC
staging scheme. Thus, we performed RPA to derive a new
Fig. 2 Refined stage grouping for resectable pancreatic ductal adenocarcinoma on the basis of RPA
Fig. 3 Overall survival of patients with resectable pancreatic ductal
adenocarcinoma stratified by RPA stage. Each RPA stage represents a
distinct prognosis
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staging scheme of resectable PDAC which incorporated the
prognostic impact of tumor grade and 8th AJCC stage.
The RPA staging scheme outperformed the 8th AJCC
staging scheme in terms of discriminatory power and
prognostic homogeneity. Although the discrimination was
only moderately better, the prognostic homogeneity was
considerably better for the RPA staging system. On the one
hand, OS was homogeneous within each RPA stage
regardless of the 8th AJCC stages. For example, high-grade
T1N0 and low-grade T2N0 tumors, which were classified
into different prognostic subgroups on the basis of the 8th
AJCC staging (8th stage IA and IB, respectively), actually
had similar survival and both were re-classified into RPA-
IB. On the other hand, each 8th AJCC stage group could be
classified by the RPA system into subgroups with
remarkably different OS rates. For example, the 8th stage
IA disease (8th T1N0) was further stratified into RPA-IB
and RPA-IA disease depending on tumor grade, and the
difference in median survival between patients in these two
groups was almost 20 months.
Wasif et al. [7] have combined tumor grade and the 7th
AJCC stage into a novel TNMG system, which exhibited
superior survival discrimination to the 7th AJCC staging
scheme. However, this scheme was based on arbitrary
regrouping of patients within different risk groups, which is
methodologically not sound [7]. Moreover, the TNMG
system was derived from the 7th AJCC staging, of which
the T3 classification (resectable PDAC extending beyond
the pancreas) exhibited poor reproducibility among
pathologists [14]. In contrast, the current RPA staging
scheme was built upon the objective combination of tumor
grade and the newly proposed 8th AJCC stage, of which
the T classification has shown favorable reproducibility
among different institutions [9].
For more accurate survival prediction in patients with
PDAC, extensive efforts have been made for the
development of prognostic nomograms which combined
various prognosticators, such as the one created by the
Memorial Sloan-Kettering Cancer Center [4]. However,
these nomograms have not been widely accepted by
patients and clinicians, probably because they are cum-
bersome to apply and inherently complex. In contrast,
although the proposed RPA staging scheme was built upon
the combination of tumor grade and 8th AJCC stage, it is a
simple system which consists of five well-defined stage
groups. Thus, it is of importance that the improved prog-
nostic performance of the RPA staging scheme over the 8th
AJCC staging scheme was not at the cost of complexity
and ease of use in prognosis and treatment planning.
The proposed RPA staging scheme is clinically mean-
ingful under the current treatment modality of
resectable PDAC. Currently, international guidelines rec-
ommend adjuvant chemotherapy followed by curative
surgery of PDAC, with the optimal chemotherapy regimen
remaining unsettled [15, 16]. Additionally, the OS benefit
from adjuvant chemotherapy was modest (difference in
median OS: \5 months) according to the results of the
CONKO-001 trial [17] and the ESPAC-1 trial [18]. The
proposed RPA staging scheme, which had superior prog-
nostic performance to the 8th AJCC staging, will be clin-
ically useful in treatment planning, such as evaluating the
administration of adjuvant chemotherapy and the trade-offs
between chemotherapy regimens. Moreover, it may also
help risk stratification of patients entering future clinical
trials.
The present study has several limitations. First, even
though the SEER database is checked regularly for dis-
crepancy and reportedly has 95 % accuracy, the possibility
of coding errors remains. Additionally, the measurement of
tumor size of PDAC may not always be accurate due to the
difference in the percentage of tumor mesenchyme, the
condition of chronic pancreatitis, and the experience of
Table 2 Comparison of prognostic homogeneity between the 8th AJCC staging and the RPA staging
Staging
scheme












IA 477 42 months 166 23 months – – – – – – <0.01
IB – – 1010 26 months 470 18 months – – – – <0.001
IIA – – – – 340 20 months 187 15 months – – 0.04
IIB – – – – 2024 19 months 1293 14 months – – <0.001
III – – – – – – 1012 17 months 740 12 months <0.001
P value§ – 0.92 0.51 0.07 –
AJCC American Joint Committee on Cancer, RPA recursive partition analysis
* Comparison of median survival within different RPA stages. Bold P values indicate statistical significance (i.e., P\ 0.05)
§ Comparison of median survival within different 8th AJCC stages. Bold P values indicate statistical significance (i.e., P\ 0.05)
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pathologists. Moreover, because information regarding
adjuvant chemotherapy was not available in the SEER
database, we were not able to assess how the proposed
RPA staging may influence patient selection for adjuvant
chemotherapy. Finally, although the proposed RPA staging
performed well during internal validation using boot-
strapped resampling, external validation using patient
cohorts from other countries outside the USA is required.
Despite these limitations, the use of the SEER data enables
us to draw solid conclusions pertinent to the general clin-
ical practice on the basis of a large sample of patients with
PDAC, which is not possible in single-institution studies.
In summary, we demonstrated that high tumor grade was
associated with poor prognosis among patients with
resectable PDAC across all 8th AJCC stages, suggesting
the 8th AJCC staging needed improvement. Accordingly,
we used RPA to develop a refined staging scheme which
incorporated the prognostic information of tumor grade and
8th AJCC stage for patients with resectable PDAC. The
RPA staging outperformed the 8th AJCC staging but was
not substantially more complex. This newly proposed
staging system will be clinically useful for prognosis,
surveillance, and treatment planning, as well as risk strat-
ification in future clinical trials for patients with
resectable PDAC.
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